CClinicalTrials.gg
Sign In
Status unknownNCT03225456Updated Jul 21, 2017

Oxytocin and Eating

A Phase 2 interventional study of Syntocinon and Placebos in Weight Gain, sponsored by Yale-NUS College. Status unknown at 1 site in Singapore. Open to male participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by Yale-NUS College · Phase 2, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
Male
01

Study summary

In this protocol, the investigators propose a randomised controlled trial to explore the effects of intra-nasal oxytocin administration on appetite regulation. The investigators will run a cross-over design with 60 healthy adult men.

02

Conditions studied

  • Weight Gain

Browse trials for

Keywords

  • appetite regulation
  • obesity
  • oxytocin
03

In context

Weight Gain

405 studies on the registry are indexed under Weight Gain; 52 are open to participants now.

This study's planned enrollment of 60 is below the median of 83 across 324 interventional studies indexed under Weight Gain.

Browse Weight Gain studies →

Lead sponsor

Yale-NUS College is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Gender: Male
  • Age: 21-45 years
  • Normal weight: Body mass index of 18.5 to 22.9
  • Have had a stable weight for the past 3 months (less than 5kg)
  • Have regular breakfast meals (≥ 4 times a week of self-reported consumption of a breakfast meal)
  • Have habitual sleep of 6.5-8.5 hours
  • Have English as first language (or fluent in spoken and written English)

Exclusion criteria

Exclusion Criteria:

  • Symptoms / history of any major medical condition, including:

    • Bariatric surgery or surgical obesity treatment
    • Diabetes
    • Cardiovascular disease
    • Thyroid disease
    • Anaemia
    • Psychiatric disorders
    • Eating disorders
  • Excessive exercise (running > 40 km or exercising > 10 hr in a week)
  • Currently on a special diet or trying deliberately to restrict food intake
  • Currently on a weight loss program
  • Smoking or substance abuse
  • Use of medications that can affect weight (e.g., steroids, approved weight-loss drugs)
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Oxytocin

    Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session

    Drug: Syntocinon

  • Placebo comparator
    Placebo

    Participants will received match placebo, again in two doses in a single session

    Drug: Placebos

Interventions

  • DrugSyntocinon

    Intra-nasal oxytocin

  • DrugPlacebos

    Intra-nasal placebo

06

What researchers measure

Primary outcomes

  1. Taste sensitivity

    Taste thresholds for primary taste senses, measured using psychophysical staircase procedures

    Time frame: 2-hour span following oxytocin administration

  2. Taste preference

    Measured using the positive/negative generalised Labeled Magnitude Scale used to assess pleasantness

    Time frame: 2-hour span following oxytocin administration

  3. Value placed upon food

    Willingness to pay for food (vs non-food items) in a Becker-DeGroot-Marschak auction task

    Time frame: 2-hour span following oxytocin administration

Secondary outcomes

  1. Subjective ratings of hunger and fullness

    Measured using 100-point Visual Analogue Scales

    Time frame: 2-hour span following oxytocin administration

07

Study locations

1 site
  • Yale-NUS College
    Singapore, 138527, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03225456
Lead sponsor
Yale-NUS College
Collaborators
Singapore General Hospital, SingHealth Investigational Medicine Unit
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Sep 2017 (estimated)
Primary completion
Dec 2018 (estimated)
Completion
Jan 2019 (estimated)
Last update
Jul 21, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Weight Gain→

Other studies from this sponsor

Yale-NUS College

Start the discussion